Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform models the human immune system in a way that current technologies cannot to rapidly discover drugs, generate immunotherapies, and identify novel drug targets. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years. Our platform was validated at Stanford and published in a top-tier journal, and is generating commercial traction with pharma, the Federal government, and large R&D organizations. Our seed round—led by Refactor Capital, Breakout Ventures, and Y Combinator—is currently being used to build our lab and team in Los Angeles, build out our IP portfolio, and close a major partnership.